AstraZeneca and Janssen to jointly promote prostate cancer treatment in Japan

UK-based drugmaker AstraZeneca and Janssen Pharmaceuticals K.K have entered into a co-promotion agreement for a new oral therapy called abiraterone acetate, a CYP17-inhibitor, to treat prostate cancer patients.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news